NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 130 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.07 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,000 | -16.7% | 9,191 | +102.1% | 0.00% | – |
| Q2 2023 | $12,000 | -14.3% | 4,547 | +30.3% | 0.00% | – |
| Q1 2023 | $14,000 | -50.0% | 3,490 | -37.0% | 0.00% | – |
| Q4 2022 | $28,000 | -31.7% | 5,542 | +73.5% | 0.00% | – |
| Q3 2022 | $41,000 | +355.6% | 3,195 | +353.2% | 0.00% | – |
| Q2 2022 | $9,000 | -75.0% | 705 | -69.5% | 0.00% | – |
| Q1 2022 | $36,000 | -64.0% | 2,314 | -59.3% | 0.00% | – |
| Q4 2021 | $100,000 | +66.7% | 5,687 | +96.4% | 0.00% | – |
| Q3 2021 | $60,000 | +39.5% | 2,895 | +34.2% | 0.00% | – |
| Q2 2021 | $43,000 | -10.4% | 2,157 | +30.7% | 0.00% | – |
| Q1 2021 | $48,000 | -99.6% | 1,650 | -99.8% | 0.00% | -100.0% |
| Q1 2020 | $11,516,000 | -33.4% | 933,959 | -0.2% | 0.01% | 0.0% |
| Q4 2019 | $17,301,000 | +3.4% | 935,675 | -22.6% | 0.01% | -14.3% |
| Q3 2019 | $16,735,000 | -5.4% | 1,208,367 | -0.0% | 0.01% | 0.0% |
| Q2 2019 | $17,691,000 | – | 1,208,433 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |